22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
22:51 , Jan 24, 2019 |  BioCentury  |  Emerging Company Profile

Caelus' microbes for metabolic syndrome

Of the handful of companies aiming to harness the therapeutic potential of the microbiome, Caelus Health is the first to reach the clinic with a bacterial therapeutic for metabolic syndrome: an oral formulation of Eubacterium...
20:28 , Feb 3, 2017 |  BC Week In Review  |  Company News

J&J, Caelus deal

Caelus joined Johnson & Johnson’s Belgium-based JLINX incubator and will gain access to the computational resources of J&J’s Janssen Human Microbiome Institute (JHMI) for use in identifying potential microbiome-based therapies. Caelus’ lead candidate, CP-001 ,...
23:34 , Feb 2, 2017 |  BC Extra  |  Company News

Caelus investment among J&J's microbiome deals

The Janssen Human Microbiome Institute (JHMI) of Johnson & Johnson (NYSE:JNJ) announced three microbiome-related deals Thursday, including an equity investment in cardiometabolic company Caelus Health (Amsterdam, the Netherlands). J&J’s Johnson & Johnson Innovation-JJDC Inc. venture...
00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...